Many Quest Diagnostics Incorporated(DGX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Quest Diagnostics Inc was Initiated by Deutsche Bank on Jan 18, 2017 to Buy, Price Target of the shares are set at $108.Quest Diagnostics Inc was Upgraded by Mizuho on Jan 3, 2017 to Buy, Price Target of the shares are set at $103.Quest Diagnostics Inc was Upgraded by Goldman to Buy on Dec 12, 2016.
Company has reported several Insider transactions to the SEC, on Feb 6, 2017, Michael E Prevoznik (SVP & General Counsel) sold 45,000 shares at 92.39 per share price.On Feb 1, 2017, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 80,000 shares at 90.81 per share price.On Nov 17, 2016, Gary M Pfeiffer (director) sold 42,643 shares at 85.09 per share price.
Quest Diagnostics Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $1.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04. Analyst had a consensus of $1.27. The company had revenue of $1861.00 million for the quarter, compared to analysts expectations of $1859.20 million. The companys revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.29 EPS.
Quest Diagnostics Incorporated (NYSE:DGX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.78 by 17 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 12 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell. A sell rating was given by 1 analyst.
Quest Diagnostics Incorporated (NYSE:DGX): The mean short term price target for Quest Diagnostics Incorporated (NYSE:DGX) has been established at $90.75 per share. The higher price target estimate is at $108 and the lower price target estimate is expected at $78 according to 12 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $9.35
Quest Diagnostics Incorporated (NYSE:DGX) rose 0.69% or 0.65 points on Tuesday and made its way into the gainers of the day. After trading began at $93.76 the stock was seen hitting $94.6699 as a peak level and $93.76 as the lowest level. The stock ended up at $94.61. The daily volume was measured at 766,077 shares. The 52-week high of the share price is $95.14 and the 52-week low is $61.9. The company has a market cap of $12,962 million.
Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.